AJMC news story
Success in HIV management often comes down to the details, and as clinicians increasingly embrace long-acting injectables, one detail is proving critical: hepatitis B virus (HBV) status. At CROI 2026, the conversation shifted to a growing safety concern — the potential for HBV reactivation in patients transitioning away from tenofovir-based oral antiretroviral therapy (ART). Laurence Brunet, PhD, of Epividian, and Gerald Pierone, MD, chief medical officer of Whole Family Health Center, sat down to parse new findings that reveal how often baseline HBV screening is missed in clinical practice, creating a preventable risk for patients making the switch.
Read the full news story here.
View all AJMC reports from CROI 2026
Source : AJMC
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.